Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Conditions
Interventions
Idasanutlin
Cytarabine
+2 more
Locations
26
United States
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States
University of Iowa Hospitals and Clinics; Investigational Drug Services
Iowa City, Iowa, United States
University of Kansas Clinical Research Center; Clinical Trials Office
Fairway, Kansas, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
March 25, 2019
Primary Completion Date
September 10, 2020
Completion Date
September 10, 2020
Last Updated
June 21, 2022
NCT05564390
NCT03050268
NCT07320235
NCT06782542
NCT06439199
NCT05886049
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions